Analystreport

Eiger Biopharmaceuticals Inc. (NASDAQ: EIGR) had its price target raised by analysts at Piper Jaffray to $28.00. They now have an "overweight" rating on the stock.

Eiger BioPharmaceuticals, Inc.  (EIGR) 
Last eiger biopharmaceuticals, inc. earnings: 3/13 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.eigerbio.com